Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Cognitive Behavior Group Therapy in Adolescents (14-18 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
NCT number | NCT02937142 |
Other study ID # | 2015/2115 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2017 |
Est. completion date | October 2020 |
Verified date | December 2021 |
Source | St. Olavs Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder which starts in childhood and is characterized by symptoms of attention deficit, hyperactivity and impulsivity. Persistence into adolescence is frequently associated with among other low educational achievement, interpersonal difficulties, anxious and depressive symptoms and sleep problems. Treatment guidelines recommend psychological treatment as part of the treatment plan, however compared to children and adults, there is still a substantial lack of knowledge about appropriate psychological treatment in adolescents. The present study examines a psychological intervention for adolescents with ADHD, cognitive behavior group therapy. The intervention consists of 12 weekly cognitive behavioral therapy sessions addressing core difficulties and concerns of the adolescent population with ADHD. The investigators wish to determine the efficacy of group therapy in adolescents with ADHD who receive medical treatment but still have impairing ADHD symptoms.
Status | Completed |
Enrollment | 100 |
Est. completion date | October 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 18 Years |
Eligibility | Inclusion Criteria: - Attention deficit hyperactivity disorder (ICD-10) - Clinical Global Impression (CGI) >=3 - Informed consent patient - informed consent parents - if on medication, dosage is stable since at least 2 months Exclusion Criteria: - mental retardation - behavioral problems - drug addiction - psychosis - suicidal |
Country | Name | City | State |
---|---|---|---|
Norway | Barne- og ungdomspsykiatrisk poliklinikk, St Olavs Hospital | Trondheim |
Lead Sponsor | Collaborator |
---|---|
St. Olavs Hospital | Norwegian University of Science and Technology |
Norway,
Nøvik TS, Haugan AJ, Lydersen S, Thomsen PH, Young S, Sund AM. Cognitive-behavioural group therapy for adolescents with ADHD: study protocol for a randomised controlled trial. BMJ Open. 2020 Mar 25;10(3):e032839. doi: 10.1136/bmjopen-2019-032839. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ADHD-Rating Scale (ADHD-RS) | interview | 12 weeks (at baseline and immediately after the last group therapy session) | |
Secondary | ADHD-Rating Scale (ADHD-RS) | 9 months | ||
Secondary | Clinical Global Impression (CGI) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Weiss Functional Impairment Rating Scale (WFIRS) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Weiss Functional Impairment Rating Scale (WFIRS) | 9 months | ||
Secondary | Children's Global Assessment Scale (CGAS) | 9 months | ||
Secondary | Anxiety symptoms (SCARED) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Depressive symptoms (Mood and Feelings Questionnaire (MFQ) Norwegian version "Humøret ditt") | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Sleep problems (Adolescent Sleep Wake Scale | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Self-esteem (Rosenberg Self-Esteem Scale) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Self-esteem (Rosenberg Self-Esteem Scale) | 9 months | ||
Secondary | Self-efficacy (General Perceived Self-Efficacy Scale) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Self-efficacy (General Perceived Self-Efficacy Scale) | 9 months | ||
Secondary | Executive functioning (Behavior Rating Scale of Executive Functioning, BRIEF) | 12 weeks (at baseline and immediately after the last group therapy session) | ||
Secondary | Executive functioning (Behavior Rating Scale of Executive Functioning, BRIEF) | 9 months | ||
Secondary | ASEBA Brief Problem Monitor | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |